| 1 |
Erika P, Kristina NW, Christopher AH, et al. Management of malignant pleural effusion: challenges and solutions[J]. Cancer Manag Res, 2017, 9: 229-241.
|
| 2 |
Labib GD, David EO. Advances in the management of malignant pleural effusion[J]. Curr Opin Pulm Med, 2017, 23(4): 317-322.
|
| 3 |
Taghizadeh N, Fortin M, Tremblay A. US Hospitalizations for malignant pleural effusions: Data from the 2012 National inpatient sample[J]. Chest, 2017, 151(4): 845-854.
|
| 4 |
Coenraad FNK, Jane AS, Elvis MI, et al. Contemporary best practice in the management of malignant pleural effusion[J]. Ther Adv Respir Dis, 2018, 12: 1753466618785098.
|
| 5 |
Desai NR, Lee HJ. Diagnosis and management of malignant pleural effusions: state of the art in 2017[J]. J Thorac Dis, 2017, 9(Suppl 10): S1111-S1122.
|
| 6 |
Nevenka PZ, Igor C, Nina PN, et al. A Retrospective study of ultrasound characteristics and macroscopic findings in confirmed malignant pleural effusion[J]. Pulm Med, 2019, 2019: 5628267.
|
| 7 |
Jiang B, Li XL, Yin Y, et al. Ultrasound elastography: a novel tool for the differential diagnosis of pleural effusion[J]. Eur Respir J, 2019, 54(2): 1802018.
|
| 8 |
Rachelle A, Najib MR. Malignant pleural effusion: From diagnostics to therapeutics[J]. Clin Chest Med, 2018, 39(1): 181-193.
|
| 9 |
Porcel JM, Pardina M, Bielsa S, et al. Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions[J]. Chest, 2015, 147(2): 513-519.
|
| 10 |
José MP, Paula H, Montserrat MA, et al. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis[J]. Chest, 2015, 147(2): 502-512.
|
| 11 |
Yang MF, Tong ZH, Wang Z, et al. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion[J]. Eur J Nucl Med Mol Imaging, 2019, 46(7): 1457-1467.
|
| 12 |
Lepus CM, Vivero M. Updates in effusion cytology[J]. Surg Pathol Clin, 2018, 11(3): 523-544.
|
| 13 |
Horiana BG, Farah K, Erik V, et al. Sensitivity of initial thoracentesis for malignant pleural effusion stratified by tumor type in patients with strong evidence of metastatic disease[J]. Respiration, 2018, 96(4): 363-369.
|
| 14 |
Aboudara M, Maldonado F. Update in the management of pleural effusions[J]. Med Clin North Am, 2019, 103(3): 475-485.
|
| 15 |
Sachdeva A, Shepherd RW, Lee HJ. Thoracentesis and thoracic ultrasound: state of the art in 2013[J]. Clin Chest Med, 2013, 34(1): 1-9.
|
| 16 |
Anevlavis S, Froudarakis ME. Advances in pleuroscopy[J]. Clin Respir J, 2018, 12(3): 839-847.
|
| 17 |
Fitzgerald DB, Koegelenberg CFN, Yasufuku K, et al. Surgical and non-surgical management of malignant pleural effusions[J]. Expert Rev Respir Med, 2018, 12(1): 15-26.
|
| 18 |
Porcel JM, Civit C, Esquerda A, et al. Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience[J]. Arch Bronconeumol, 2017, 53(8): 427-431.
|
| 19 |
Creaney J, Robinson BWS. Malignant mesothelioma biomarkers: From discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment[J]. Chest, 2017, 152(1): 143-149.
|
| 20 |
Cui A, Jin XG, Zhai K, et al. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.[J]. BMJ Open, 2014, 4(2): e004145.
|
| 21 |
Ian W, Lesley B, Liz D, et al. British thoracic society guideline for the investigation and management of malignant pleural mesothelioma[J]. Thorax, 2018, 73 (Suppl 1): i1-i30.
|
| 22 |
Pei DX, Li YW, Liu XW，et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis[J]. Oncotarget, 2017, 8(8): 13030-13038.
|
| 23 |
Ren R, Yin PP, Zhang Y, et al. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(51): 84851-84859.
|
| 24 |
Andrew C, Brandon SS, Francoise GS. New markers for separating benign from malignant mesothelial proliferations: Are we there yet？[J]. Arch Pathol Lab Med, 2016, 140(4): 318-321.
|
| 25 |
José MP. Biomarkers in the diagnosis of pleural diseases: a 2018 update[J]. Ther Adv Respir Dis, 2018, 12: 1753466618808660.
|
| 26 |
Ben D, Martin T, Jeremias W, et al. The diagnostic role of BAP1 in serous effusions[J]. Hum Pathol, 2018, 79: 122-126.
|
| 27 |
Janick S, Elodie LM, Marie CM, et al. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site[J]. Cancers (Basel), 2018, 10(4): 108.
|
| 28 |
Losa F, Iglesias L, Pane M, et al. 2018 consensus statement by the Spanish society of pathology and the Spanish society of medical oncology on the diagnosis and treatment of cancer of unknown primary[J]. Clin Transl Oncol, 2018, 20(11): 1361-1372.
|
| 29 |
Ettinger DS, Aisner DL, Wood DE, et al. NCCN Guidelines Insights：Non-small cell lung cancer, version 5.2018[J]. J Natl Compr Canc Netw, 2018, 16(7): 807-821.
|
| 30 |
Martin R, Klaus FR. Precision diagnosis and treatment for advanced non-small cell lung cancer[J]. N Engl J Med, 2017, 377(9): 849-861.
|
| 31 |
Deborah BD, Roy SH. Treatment of advanced non-small cell lung cancer in 2018[J]. JAMA Oncol, 2018, 4(4): 569-570.
|
| 32 |
Lamiaa MK, Dina MA, Amal MHM, et al. Circulating long non-coding RNA GAS5 and SOX2OT as potential biomarkers for diagnosis and prognosis of non-small cell lung cancer[J]. Biotechnol Appl Biochem, 2019, 66(4): 634-642.
|
| 33 |
Daniel GW, Katarzyna G, Swaantje C, et al. Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma[J]. Dis Markers, 2017, 2017: 9280170.
|
| 34 |
Wang C, Peng J, Kuang Y, et al. Metabolomic analysis based on 1H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion[J]. Mol Med Rep, 2017, 16(2): 1147-1156.
|
| 35 |
Zennaro L，Vanzani P, Nicole L, et al. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers[J]. Cancer Cytopathol, 2017, 125(5): 341-348.
|
| 36 |
Di X, Jin X, Li R, et al. CircRNAs and lung cancer: Biomarkers and master regulators[J]. Life Sci, 2019, 220: 177-185.
|